2024 年第 1 期 第 19 卷

白细胞介素6与核因子κB对胰腺癌的诊断价值及其与临床病理分期的关系研究

The value of interleukin-6 and nuclear factor-κB in the diagnosis of pancreatic cancer and the relationship with clinicopathological staging

作者：崔彦杰1 宋金萍1 徐辉2

英文作者：Cui Yanjie1， Song Jinping1， Xu Hui2

单位：1新疆维吾尔自治区人民医院临床检验中心，乌鲁木齐830001；2新疆维吾尔自治区人民医院胰腺外科，乌鲁木齐830001

英文单位：1Clinical Laboratory Center， People′s Hospital of Xinjiang Uygur Autonomous Region Urumqi 830001， China; 2Department of Pancreatic Surgery People′s Hospital of Xinjiang Uygur Autonomous Region， Urumqi 830001， China

关键词：胰腺癌；白细胞介素6；核因子κB

英文关键词：Pancreaticcancer；Interleukin-6；Nuclearfactor-κB

• 摘要：

• 目的  探究白细胞介素6（IL-6）、核因子κB（NF-κB）对胰腺癌的诊断价值及其与胰腺癌临床病理分期的关系。方法  收集2019年6月至2022年6月新疆维吾尔自治区人民医院收治的68例胰腺癌患者作为病例组，60例同期于本院门诊健康体检者作为对照组。检测2组受试者血清中IL-6、NF-κB的表达水平，采用受试者工作特征（ROC）曲线分析IL-6、NF-κB表达对胰腺癌诊断的价值；比较不同临床病理分期患者血清IL-6、NF-κB水平的表达差异。结果  病例组患者血清IL-6和NF-κB水平明显高于对照组，差异有统计学意义［IL-6：16.33（8.41，67.41）ng/L比6.15（5.55，7.33）ng/L，Z=6.109，P<0.001；NF-κB：449.52（230.37，568.28）ng/L比150.35（126.48，167.30）ng/L，Z=5.463，P<0.001］。IL-6、NF-κB 诊断胰腺癌ROC曲线下面积（AUC）分别为0.813±0.041、0.920±0.024，联合检测的AUC为0.923±0.024。T3、T4期胰腺癌患者血清IL-6、NF-κB水平与T1、T2期患者比较差异均有统计学意义（均P<0.05）。血清IL-6、NF-κB水平随着淋巴结转移程度（N0～N2）的增高而增高，差异均有统计学意义（均P＜0.05），且N1、N2期胰腺癌患者血清IL-6、NF-κB水平与N0期患者相比，差异均有统计学意义（均P<0.05）。远处转移胰腺癌患者（M1）的血清IL-6、NF-κB水平高于未远处转移的患者（M0），差异有统计学意义（P=0.024）。结论  血清IL-6、NF-κB可以作为胰腺癌早期诊断、临床病理分期的血清学标志物，其可能与胰腺癌的发生、发展密切相关。

• Objective  To explore the value of interleukin-6 (IL-6) and nuclear factor-κB (NF-κB) in the diagnosis of pancreatic cancer, and to analyze the correlation between the expression level of the two cytokines and the clinicopathological stage of pancreatic cancer. Methods  Totally 68 patients with pancreatic cancer admitted to People′s Hospital of Xinjiang Uygur Autonomous Region from June 2019 to June 2022 were selected as the case group, and 60 healthy subjects who underwent physical examination in the outpatient department of the hospital were selected as the control group. The expression levels of IL-6 and NF-κB in serum of the two groups were detected. Receiver operating characteristic (ROC) curve was prepared to analyze the value of IL-6 and NF-κB expression in the diagnosis of pancreatic cancer. The expression of serum IL-6 and NF-κB in patients with different clinicopathological stages were compared. Results  Serum levels of IL-6 and NF-κB in the case group were significantly higher than those in the control group［IL-6:16.33(8.41, 67.41)ng/L vs 6.15(5.55, 7.33)ng/L, Z=6.109, P<0.001; NF-κB: 449.52(230.37, 568.28)ng/L vs 150.35(126.48, 167.30)ng/L, Z=5.463, P<0.001］. The area under the ROC curve (AUC) for IL-6 and NF-κB in diagnosing pancreatic cancer was 0.813±0.041 and 0.920±0.024, respectively, and the AUC for combined detection was 0.923±0.024. Serum IL-6 and NF-κB levels were significantly different between T3, T4 pancreatic cancer patients and T1, T2 patients (all P<0.05). Serum levels of IL-6 and NF-κB increased with the increase of the degree of lymph node metastasis (N0-N2), and the differences were statistically significant (all P<0.05). The serum levels of IL-6 and NF-κB in patients with pancreatic cancer stage N1 and N2 were statistically significant compared with those in patients with N0 stage (all P<0.05). The serum levels of IL-6 and NF-κB in patients with distant metastasis (M1) were higher than those without distant metastasis (M0), and the difference was statistically significant (P=0.024). Conclusion  Serum IL-6 and NF-κB can be used as serological markers in the early diagnosis and clinical stage for the diagnosis and staging of pancreatic cancer, and may be closely related to the occurrence and development of pancreatic cancer.